Please login to the form below

Not currently logged in


This page shows the latest opicapone news and features for those working in and with pharma, biotech and healthcare.

SMC approves Parkinson’s disease treatment Ongentys

SMC approves Parkinson’s disease treatment Ongentys

Bial has announced that its treatment Ongentys (opicapone) has been accepted for use within NHS Scotland after a review published by the Scottish Medicines Consortium (SMC). ... Tanith Muller, parliamentary and campaigns manager at Parkinson's UK

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's disease (approved in EU).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation